Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.
Kaelo K
Seatla
;
Ava
Avalos
;
Sikhulile
Moyo
;
Madisa
Mine
;
Thabo
Diphoko
;
Mosepele
Mosepele
;
Tendani
Gaolatlhe
;
Christopher F
Rowley
;
Dinah
Ramaabya
;
Joseph N
Jarvis
;
+2 more...
Ishmael
Kasvosve
;
Simani
Gaseitsiwe
;
(2018)
Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.
AIDS (London, England), 32 (13).
pp. 1899-1902.
ISSN 0269-9370
DOI: 10.1097/QAD.0000000000001920
;
+2 more...
Ishmael
Kasvosve
;
Simani
Gaseitsiwe
;
(2018)
Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.
AIDS (London, England), 32 (13).
pp. 1899-1902.
ISSN 0269-9370
DOI: 10.1097/QAD.0000000000001920
: There are limited data on the effectiveness of dolutegravir (DTG)-based combination antiretroviral therapy (ART) in real-life settings in southern Africa where HIV-1 subtype C predominates. We report a patient infected with HIV-1 subtype C on DTG-based ART previously exposed to raltegravir who developed multidrug resistance mutations to four antiretroviral classes. There is need for drug resistance monitoring and clinical vigilance to ensure effectiveness of HIV treatment programs even in the era of DTG-based ART.
-
picture_as_pdf - Four class drug resistant HIV_GREEN AAM.pdf
-
subject - Accepted Version
-
- Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0
Downloads